The University of Chicago Header Logo

Connection

Stuart Sprague to Renal Dialysis

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Renal Dialysis.
Stuart Sprague
Connection Strength
8.208
Renal Dialysis
  1. Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Curr Med Res Opin. 2024 Aug; 40(8):1335-1343.
    View in: PubMed
    Score: 0.748
  2. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. Kidney360. 2024 May 01; 5(5):732-742.
    View in: PubMed
    Score: 0.724
  3. Should phosphate management be limited to the KDIGO/ KDOQI guidelines? Semin Dial. 2018 07; 31(4):377-381.
    View in: PubMed
    Score: 0.484
  4. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491.
    View in: PubMed
    Score: 0.484
  5. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67.
    View in: PubMed
    Score: 0.461
  6. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66.
    View in: PubMed
    Score: 0.403
  7. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.393
  8. Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73.
    View in: PubMed
    Score: 0.356
  9. Is bone mineral density measurement of any value in a dialysis patient? Semin Dial. 2011 Jul-Aug; 24(4):433-4.
    View in: PubMed
    Score: 0.304
  10. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.268
  11. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.266
  12. When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51.
    View in: PubMed
    Score: 0.260
  13. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
    View in: PubMed
    Score: 0.253
  14. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2007 Oct; 72(7):895; author reply 895-6.
    View in: PubMed
    Score: 0.233
  15. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis. Am J Nephrol. 2024; 55(2):127-135.
    View in: PubMed
    Score: 0.179
  16. Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 11 01; 4(11):1650-1656.
    View in: PubMed
    Score: 0.177
  17. Dialysis-related amyloidosis. Minerva Urol Nefrol. 2003 Jun; 55(2):121-9.
    View in: PubMed
    Score: 0.173
  18. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6.
    View in: PubMed
    Score: 0.155
  19. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
    View in: PubMed
    Score: 0.154
  20. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
    View in: PubMed
    Score: 0.132
  21. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.
    View in: PubMed
    Score: 0.123
  22. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1330-1338.
    View in: PubMed
    Score: 0.115
  23. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
    View in: PubMed
    Score: 0.107
  24. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Nephrol Dial Transplant. 1996; 11 Suppl 3:86-90.
    View in: PubMed
    Score: 0.103
  25. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40.
    View in: PubMed
    Score: 0.098
  26. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46.
    View in: PubMed
    Score: 0.097
  27. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7.
    View in: PubMed
    Score: 0.087
  28. Serum amyloid P component: a predictor of clinical beta 2-microglobulin amyloidosis. Am J Kidney Dis. 1992 May; 19(5):427-32.
    View in: PubMed
    Score: 0.080
  29. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92.
    View in: PubMed
    Score: 0.069
  30. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8.
    View in: PubMed
    Score: 0.069
  31. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72.
    View in: PubMed
    Score: 0.062
  32. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45.
    View in: PubMed
    Score: 0.061
  33. Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008 Jun; 73(11):1275-81.
    View in: PubMed
    Score: 0.060
  34. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.058
  35. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4.
    View in: PubMed
    Score: 0.054
  36. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure. J Ren Nutr. 2025 Jan; 35(1):25-34.
    View in: PubMed
    Score: 0.047
  37. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004 May; 19(5):1174-81.
    View in: PubMed
    Score: 0.045
  38. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888.
    View in: PubMed
    Score: 0.039
  39. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
    View in: PubMed
    Score: 0.035
  40. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35.
    View in: PubMed
    Score: 0.035
  41. Is beta 2-microglobulin a mediator of bone disease? Kidney Int. 1995 Jan; 47(1):1-6.
    View in: PubMed
    Score: 0.024
  42. Hypocalcemia in end-stage renal disease: a consequence of spontaneous parathyroid gland infarction. Am J Kidney Dis. 1994 Sep; 24(3):519-22.
    View in: PubMed
    Score: 0.024
  43. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9.
    View in: PubMed
    Score: 0.020
  44. Aluminum neurotoxicity: a reevaluation. Clin Neuropharmacol. 1991 Apr; 14(2):179-85.
    View in: PubMed
    Score: 0.019
  45. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May; 55(5):773-99.
    View in: PubMed
    Score: 0.017
  46. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54.
    View in: PubMed
    Score: 0.017
  47. Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Blood Purif. 2005; 23(4):287-97.
    View in: PubMed
    Score: 0.012
  48. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.010
  49. Factors affecting tissue aluminum concentration. J Dial. 1978; 2(5-6):471-81.
    View in: PubMed
    Score: 0.007
  50. Determinants of tissue aluminum concentration. Am J Kidney Dis. 1981 Nov; 1(3):141-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.